Literature DB >> 12541157

Bactericidal activity response of blood neutrophils from critically ill patients to in vitro granulocyte colony-stimulating factor stimulation.

Kun Yang1, Elie Azoulay, Lynda Attalah, Jean-Ralph Zahar, Andry Van de Louw, Charles Cerf, Claude-James Soussy, Philippe Duvaldestin, Laurent Brochard, Christian Brun-Buisson, Alain Harf, Christophe Delclaux.   

Abstract

OBJECTIVE: Neutrophil function impairment is common in nonneutropenic critically ill patients. Whether granulocyte colony-stimulating factor (G-CSF) may be useful for preventing nosocomial infection in these patients is debated. The response of blood neutrophils from critically ill patients to G-CSF was investigated in vitro. DESIGN AND
SETTING: Prospective study, laboratory investigation in two intensive care units. PATIENTS: 52 critically ill patients without immunosuppression. MEASUREMENTS: Neutrophils obtained from 52 patients on the 5th day of their intensive care unit stay were incubated with and without G-CSF (1, 10, 100 ng/ml). Reactive oxygen species (ROS) release and bactericidal activity against Staphylococcus aureus and Pseudomonas aeruginosa were evaluated. Plasma cytokines (interleukin 10, tumor necrosis factor alpha, and G-CSF) were measured.
RESULTS: Median values (25th-75th percentiles) indicated no stimulatory effect of G-CSF on neutrophil bactericidal activity against either organism: S. aureus, 100% (95-109) of the unstimulated condition with 1 ng/ml G-CSF, and P. aeruginosa, 102% (98-109) with 1 ng/ml G-CSF. However, wide interindividual variability was found, ranging from marked inhibition to marked stimulation. Similar variability was found for ROS release. No correlations were found between ROS release and bactericidal activities against either bacterial strain. Inhibition of neutrophil bactericidal activity by G-CSF was associated with significantly higher plasma interleukin 10 concentrations. Plasma G-CSF levels were significantly higher in patients whose neutrophil bactericidal activity was unresponsive to G-CSF, suggesting G-CSF receptor downregulation.
CONCLUSIONS: The effect of G-CSF on in vitro neutrophil bactericidal activity varied widely, depending on endogenous levels of G-CSF and was not predictable based on severity scores.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12541157     DOI: 10.1007/s00134-002-1623-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  33 in total

Review 1.  Normal responses to injury prevent systemic inflammation and can be immunosuppressive.

Authors:  R S Munford; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

2.  Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study.

Authors:  V Pettilä; O Takkunen; T Varpula; A Markkola; K Porkka; V Valtonen
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

3.  Granulocyte colony-stimulating factor (G-CSF) downregulates its receptor (CD114) on neutrophils and induces gelatinase B release in humans.

Authors:  B Jilma; N Hergovich; M Homoncik; P Jilma-Stohlawetz; C Kreuzer; H G Eichler; M Zellner; J Pugin
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

4.  A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.

Authors:  S Nelson; S M Belknap; R W Carlson; D Dale; B DeBoisblanc; S Farkas; N Fotheringham; H Ho; T Marrie; H Movahhed; R Root; J Wilson
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

5.  The effects of granulocyte colony stimulating factor on chemiluminescence and lipid peroxidation of blood platelets treated with cisplatin.

Authors:  B Olas; B Wachowicz; A Buczyński
Journal:  Anticancer Drugs       Date:  2000-02       Impact factor: 2.248

6.  Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils.

Authors:  E Roilides; T J Walsh; P A Pizzo; M Rubin
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

7.  In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood.

Authors:  P G Quie; J G White; B Holmes; R A Good
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

8.  Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia.

Authors:  K Ishikawa; H Tanaka; T Matsuoka; T Shimazu; T Yoshioka; H Sugimoto
Journal:  J Trauma       Date:  1998-06

9.  Prolonged but reversible neutrophil dysfunctions differentially sensitive to granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia.

Authors:  M Lejeune; A Ferster; B Cantinieaux; E Sariban
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  6 in total

Review 1.  Year in review in Intensive Care Medicine-2003. Part 1: Respiratory failure, infection and sepsis.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoît Vallet
Journal:  Intensive Care Med       Date:  2004-05-15       Impact factor: 17.440

2.  Comparative effects of early randomized immune or non-immune-enhancing enteral nutrition on cytokine production in children with septic shock.

Authors:  George Briassoulis; Olga Filippou; Maria Kanariou; Tassos Hatzis
Journal:  Intensive Care Med       Date:  2005-04-16       Impact factor: 17.440

3.  Evidence for bistable bacteria-neutrophil interaction and its clinical implications.

Authors:  Roy Malka; Baruch Wolach; Ronit Gavrieli; Eliezer Shochat; Vered Rom-Kedar
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

4.  Critical care management of patients with hemophagocytic lymphohistiocytosis.

Authors:  Sophie Buyse; Luis Teixeira; Lionel Galicier; Eric Mariotte; Virginie Lemiale; Amélie Seguin; Philippe Bertheau; Emmanuel Canet; Adrienne de Labarthe; Michaël Darmon; Michel Rybojad; Benoit Schlemmer; Elie Azoulay
Journal:  Intensive Care Med       Date:  2010-06-08       Impact factor: 17.440

5.  Phytotherapeutic effects of Echinacea purpurea in gamma-irradiated mice.

Authors:  Amira M K Abouelella; Yasser E Shahein; Sameh S Tawfik; Ahmed M Zahran
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

Review 6.  Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?

Authors:  Elie Azoulay; Christophe Delclaux
Journal:  Intensive Care Med       Date:  2003-10-31       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.